#75 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians need to understand that expanded access to investigational cannabis and ibogaine through Right to Try pathways may create new treatment options for patients with serious conditions while also generating documentation gaps in their medical records. These legislative changes could shift the informed consent conversation, requiring providers to discuss unproven therapies and their lack of established safety profiles with patients seeking alternatives to standard care. Staying informed about state-level Right to Try laws helps clinicians navigate ethical obligations, liability considerations, and the evolving regulatory landscape around cannabis and novel psychedelic treatments.
Two significant pieces of legislation have advanced toward gubernatorial approval: the Right to Try Medical Cannabis Act and provisions enabling ibogaine clinical trials. The Right to Try Medical Cannabis Act would expand patient access to cannabis outside of standard clinical trial frameworks, potentially allowing individuals with serious conditions to use cannabis products before full regulatory approval is completed. This legislative development mirrors similar “right to try” frameworks in other states and could create new pathways for patients seeking cannabis-based treatments who have exhausted conventional options. The concurrent advancement of ibogaine clinical trials represents growing regulatory openness to investigating novel psychedelic compounds for therapeutic purposes, though ibogaine research remains distinct from cannabis medicine. Clinicians should anticipate potential changes to their prescribing landscape and patient counseling regarding off-label cannabis access if these bills become law. These developments underscore the evolving regulatory environment around cannabis and novel therapeutics, requiring clinicians to stay informed about expanded access options and their associated evidence bases to appropriately counsel patients.
“Right to Try legislation for cannabis represents a significant shift in how we approach end-of-life and treatment-resistant conditions, and it acknowledges what many of us in clinical practice have already observed: some patients derive genuine benefit from cannabis when conventional options have failed, and denying them access based purely on regulatory timelines rather than medical evidence serves neither ethics nor outcomes.”
🏥 The passage of Right to Try legislation for medical cannabis and ibogaine represents an expansion of compassionate access pathways that clinicians should understand, even as evidence bases for these substances remain limited and heterogeneous. While these laws potentially offer options for patients with treatment-resistant conditions who have exhausted standard therapies, providers will need to carefully distinguish between expanded legal access and established clinical efficacy, particularly given the lack of large randomized controlled trials for cannabis in most indications and the extremely limited human data on ibogaine. The regulatory framework for these substances will likely differ substantially from conventional pharmaceuticals, creating uncertainty around dosing standardization, drug interactions, contamination risks, and monitoring protocols that clinicians must navigate. Healthcare providers should prepare for patient inquiries about these options by reviewing available evidence, understanding state-specific regulations as they develop, and maintaining realistic conversations about both potential benefits and genuine safety gaps. Ultimately, clinicians will need to exercise careful judgment
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: